This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

Genscript Biotech ( (HK:1548)) just unveiled an announcement. Genscript Biotech reported a sharp acceleration in operating performance for 2025, with revenue from continuing operations surging 61.4% ...

Detailed price information for Genscript Biotech Corp (GNNSF) from The Globe and Mail including charting and trades.

Nvidia (NVDA) and Eli Lilly (LLY, down 7% YTD, forward P/E under 30x) in $1B partnership. Eli Lilly deploys AI for drug discovery via Nvidia partnership and LillyPod supercomputer as biotech provides ...

The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering rate, especially among the Mag Seven AI darlings, all while the question ...

The merger will see Rallybio acquire Candid, which has secured over $505 million in financing from a syndicate of leading healthcare institutional investors. Pro-forma cash of approximately $700 ...

(Check out Carter's worthcharting.com for actionable recommendations and live nightly videos.) Mid-cap biotech Immunovant is judged to be setup especially well for a move higher, by our work. In the ...